Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein Sells 57,764 Shares

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 57,764 shares of Insmed stock in a transaction on Monday, July 7th. The stock was sold at an average price of $95.86, for a total value of $5,537,257.04. Following the sale, the chief financial officer owned 84,017 shares in the company, valued at $8,053,869.62. The trade was a 40.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Monday, June 23rd, Sara Bonstein sold 57,765 shares of Insmed stock. The stock was sold at an average price of $101.78, for a total value of $5,879,321.70.
• On Tuesday, June 10th, Sara Bonstein sold 57,766 shares of Insmed stock. The stock was sold at an average price of $89.12, for a total value of $5,148,105.92.
• On Tuesday, June 3rd, Sara Bonstein sold 1,579 shares of Insmed stock. The stock was sold at an average price of $71.50, for a total value of $112,898.50.
• On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total value of $107,206.74.
• On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total value of $601,474.70.

Insmed Price Performance

NASDAQ:INSM traded up $1.52 during mid-day trading on Friday, reaching $98.18. The stock had a trading volume of 3,244,487 shares, compared to its average volume of 2,282,446. The firm has a 50 day moving average price of $83.40 and a two-hundred day moving average price of $77.39. The stock has a market capitalization of $18.63 billion, a P/E ratio of -16.50 and a beta of 0.90. Insmed, Inc. has a one year low of $60.40 and a one year high of $106.83. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.06) EPS. As a group, analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Institutional Trading of Insmed

Hedge funds have recently bought and sold shares of the company. OneDigital Investment Advisors LLC lifted its position in Insmed by 47.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock worth $399,000 after buying an additional 1,673 shares during the last quarter. Sowell Financial Services LLC bought a new stake in Insmed in the 1st quarter worth approximately $255,000. GAMMA Investing LLC lifted its position in Insmed by 62.0% in the first quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 386 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Insmed by 16.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock valued at $288,000 after purchasing an additional 541 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its position in Insmed by 37.7% in the first quarter. Oppenheimer Asset Management Inc. now owns 19,935 shares of the biopharmaceutical company's stock valued at $1,521,000 after purchasing an additional 5,453 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on INSM. Wells Fargo & Company lifted their price objective on Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. Jefferies Financial Group reissued a "buy" rating on shares of Insmed in a report on Tuesday, June 10th. UBS Group reduced their target price on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. Bank of America lifted their target price on Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. Finally, Citigroup raised Insmed to a "buy" rating in a report on Tuesday, June 10th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $108.07.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.